Delayed amnesic syndrome after riluzole use in major depressive disorder: A case report

Psychosomatics

Volumn 54, Issue 5, 2013, Pages 488-492

  Cardoos, Amber ^a   Inamori, Aya ^a   Sanacora, Gerard ^b   Fava, Maurizio ^a   Mischoulon, David ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GABAPENTIN; PHENYTOIN; RILUZOLE; SERTRALINE; TROPONIN I;

ADULT; ALCOHOL ABUSE; AMNESIA; ARTICLE; CANNABIS ADDICTION; CASE REPORT; COCAINE DEPENDENCE; COMPUTER ASSISTED TOMOGRAPHY; DELAYED HYPERSENSITIVITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; FIBROMYALGIA; FOLLOW UP; HEROIN DEPENDENCE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA AND VOMITING; OPEN STUDY; REMISSION; SEIZURE; SUICIDAL IDEATION; TREATMENT RESPONSE; X RAY;

AMNESIA; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISSOCIATIVE DISORDERS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RILUZOLE;

EID: 84883813785     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2013.02.002     Document Type: Article

References (20)

1. Fava M., Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996, 19:179-200.
2. Zarate C.A., Payne J.L., Quiroz J., Sporn J., Denicoff K.K., Luckenbaugh D., et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171-174.
3. Mathew S.J., Amiel J.M., Coplan J.D., Fitterling H.A., Sackeim H.A., Gorman J.M. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005, 162:2379-2381.
4. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005, 58:424-428.
5. Sanacora G., Kendell S.F., Levin Y., Simen A.A., Fenton L.R., Coric V., et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007, 61:822-825.
6. Groeneveld G.J., Van Kan H.J., Kalmijn S., Veldink J.H., Guchelaar H.J., Wokke J.H., et al. Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. Neurology 2003, 61:1141-1143.7.
7. Haaxma C.A., Kremer H.P., van de Warrenburg B.P. Delayed amnesic syndrome after riluzole autointoxication in Huntington disease. Neurology 2006, 66:1123-1124.
8. Bodner T., Jenner C., Benke T., Ober A., Seppi K., Fleischhacker W.W. Intoxication with riluzole in Huntington's disease. Neurology 2001, 57:1141-1143.
9. Sanderink G.J., Bournique B., Stevens J., Petry M., Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997, 282:1465-1472.
10. Ajroud-Driss S., Saeed M., Khan H., Siddique N., Hung W.Y., Sufit R., et al. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS. Amyotroph Lateral Scler 2007, 8:305-309.
11. Zona C., Siniscalchi A., Mercuri N.B., Bernardi G. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 1998, 85:931-938.
12. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010, 15:501-511.
13. Fumagalli E., Funicello M., Rauen T., Gobbi M., Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1, and EAAC1. Eur J Pharmacol 2008, 578:171-176.
14. Gourley S.L., Espitia J.W., Sanacora G., Taylor J.R. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology (Berl) 2012, 219:805-814.
15. Papouin T., Ladépêche L., Ruel J., Sacchi S., Labasque M., Hanini M., et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150:633-646.
16. Omrani A., Melone M., Bellesi M., Safiulina V., Aida T., Tanaka K., et al. Up-regulation of GLT-1 severely impairs LTD at mossy fiber-CA3 synapses. J Physiol 2009, 587:4575-4588.
17. Malgouris C., Bardot F., Daniel M., Pellis F., Rataud J., Uzan A., et al. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989, 9:3720-3727.
18. Groeneveld G.J., van Kan H.J., Toraño J.S., Veldink J.H., Guchelaar H.J., Wokke J.H., et al. Inter- and intra-individual variability of riluzole serum concentrations in patients with als. J Neurol Sci 2001, 191:121-125.
19. De Sarro G., Siniscalchi A., Ferreri G., Gallelli L., De Sarro A. NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur J Pharmacol 2000, 408:25-34.
20. Kim J.E., Kim D.S., Kwak S.E., Choi H.C., Song H.K., Choi S.Y., et al. Anti-glutamatergic effect of riluzole: comparison with valproic acid. Neuroscience 2007, 147:136-145.